肿瘤新抗原mRNA疫苗在加速审批的背景下，肿瘤突变抗原的研究价值越来越大，为此，我们通过文献挖掘，为读者整理了各种肿瘤的已验证肿瘤突变抗原清单，我们将陆续发布在GCBI知识库公众号、浩生医疗官网。
以下是目前公布的肝癌肿瘤突变抗原肽清单，该清单均支持定制生产 (定制咨询请扫描本页右侧联系人二维码)。可定制生产：
肺癌抗原蛋白的抗原肽数量分布
肺癌抗原详情
已验证的肺癌抗原列表
| 抗原蛋白 | 抗原肽 | 呈递抗原的HLA | 验证文献 |
|---|---|---|---|
| EBNA3A nuclear protein | RYSIFFDYM | HLA-A24 | Cytolytic T-cell response against Epstein-Barr virus in lung cancer patients and healthy subjects. J Exp Clin Cancer Res 2010 |
| Mini-chromosome maintenance complex-binding protein | LLSAVLPSV | HLA-A*02:01 | Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res 2017 |
| ATP-binding cassette transporter A1 | ALIGGPPV | HLA-A*02:01 | Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res 2017 |
| Signal-regulatory protein delta | LLLELAGVTHV | HLA-A*02:01 | Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res 2017 |
| Fragile X mental retardation 1 neighbor protein | YLCSGSSYFV | HLA-A*02:01 | An Isolated TCR alphabeta Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8<sup>+</sup> T Cells To Kill and Secrete IFN-gamma in Response to Lung Adenocarcinoma Cell Lines. J Immunol 2018 |
| Fragile X mental retardation 1 neighbor protein | YLCSGSSYF | HLA-A*02:01 | An Isolated TCR alphabeta Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8<sup>+</sup> T Cells To Kill and Secrete IFN-gamma in Response to Lung Adenocarcinoma Cell Lines. J Immunol 2018 |
| Fragile X mental retardation 1 neighbor protein | YLCSGSSYF | HLA-A*02:01 | An Isolated TCR alphabeta Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8<sup>+</sup> T Cells To Kill and Secrete IFN-gamma in Response to Lung Adenocarcinoma Cell Lines. J Immunol 2018 |
| Fragile X mental retardation 1 neighbor protein | YLCSGSSYFV | HLA-A*02:01 | An Isolated TCR alphabeta Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8<sup>+</sup> T Cells To Kill and Secrete IFN-gamma in Response to Lung Adenocarcinoma Cell Lines. J Immunol 2018 |
| Fragile X mental retardation 1 neighbor protein | YLCSGSSYFV | HLA-A*02:01 | An Isolated TCR alphabeta Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8<sup>+</sup> T Cells To Kill and Secrete IFN-gamma in Response to Lung Adenocarcinoma Cell Lines. J Immunol 2018 |
| Fragile X mental retardation 1 neighbor protein | YLCSGSSYFV | HLA-A*02:01 | An Isolated TCR alphabeta Restricted by HLA-A*02:01/CT37 Peptide Redirecting CD8<sup>+</sup> T Cells To Kill and Secrete IFN-gamma in Response to Lung Adenocarcinoma Cell Lines. J Immunol 2018 |
| Chain A, Epidermal Growth Factor Receptor | LIMQLMPFGCL | HLA-A*02:01 | EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation. PLoS One 2013 |
| calcitonin isoform CT preproprotein [Homo sapiens] | FLALSILVL | HLA-A*02:01 | Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nat Commun 2018 |
| calcitonin isoform CT preproprotein [Homo sapiens] | VLLQAGSLHA | HLA-A*02:01 | Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nat Commun 2018 |
| calcitonin | LLAALVQDYL | HLA-A*02:01 | Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nat Commun 2018 |
| calcitonin isoform CT preproprotein [Homo sapiens] | CMLGTYTQDF | HLA-A*02:01 | Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nat Commun 2018 |
| melanoma antigen recognized by T-cells 1 | ELAGIGILTV | HLA-A*02:01 | Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nat Commun 2018 |
| calcitonin isoform CT preproprotein [Homo sapiens] | MGFQKFSPFLALSIL | HLA-A*02:01 | Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nat Commun 2018 |
| calcitonin isoform CT preproprotein [Homo sapiens] | GNLSTCMLGTYTQDF | HLA-A*02:01 | Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nat Commun 2018 |
| Epidermal growth factor receptor | KITDFGRAK | HLA-A*11:01 | Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination. Oncoimmunology 2016 |
| Probable E3 ubiquitin-protein ligase HERC1 | ASNASSAAK | HLA-A*11:01 | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015 |
| Probable E3 ubiquitin-protein ligase HERC1 | ASNASSAAK | HLA-A*11:01 | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015 |
| Probable E3 ubiquitin-protein ligase HERC1 | ASNASSAAK | HLA-A*11:01 | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015 |
| Probable E3 ubiquitin-protein ligase HERC1 | ASNASSAAK | HLA-A*11:01 | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015 |
| Probable E3 ubiquitin-protein ligase HERC1 | ASNASSAAK | HLA-A*11:01 | Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015 |
| Nuclear receptor subfamily 4 group A member 1 | ATSPASASK | HLA-A*11:01 | TruNeo: an integrated pipeline improves personalized true tumor neoantigen identification. BMC Bioinformatics 2020 |
| SPARC isoform 3 precursor [Homo sapiens] | YHMYIFPV | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| E3 ubiquitin-protein ligase HUWE1 [Homo sapiens] | ILPDAGQTV | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| ufm1-specific protease 2 [Homo sapiens] | LLVDAMHNQL | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| WRN [Homo sapiens] | MLLENKAVEKA | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| sacsin isoform X3 [Homo sapiens] | SVQDVSLFV | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| myb-related protein B isoform 1 [Homo sapiens] | SLLTNWPFV | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| KIAA0533 protein, partial [Homo sapiens] | FMQRLLGPQRV | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| adenylate cyclase type 4 [Homo sapiens] | FLSNFIILML | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| FLJ00145 protein, partial [Homo sapiens] | RLSCMLARLEV | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| ankyrin and armadillo repeat-containing protein isoform X10 [Homo sapiens] | LLLASTSGA | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| Dipeptidyl-peptidase 7 [Homo sapiens] | MMDYPYPTNFL | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| bone morphogenetic protein receptor type-1B isoform b precursor [Homo sapiens] | TMIEEYDSGL | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| putative L-Dopa decarboxylase, partial [Homo sapiens] | GLIPFFMVV | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| GTPase KRas isoform a [Homo sapiens] | KLVVVGACGV | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| bone morphogenetic protein receptor type-1B isoform b precursor [Homo sapiens] | TMIEEYDSG | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| c371H6.1 (KIAA0516 protein), partial [Homo sapiens] | RLDSTLLLY | HLA-A*02:01 | Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment. J Immunother Cancer 2019 |
| Acyl-Coenzyme A dehydrogenase family, member 8 | QTDVGGSGLSRLDISVIFEALATGCTS | HLA-A*02:01 | Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses. Front Oncol 2021 |
| breast cancer anti-estrogen resistance protein 1 isoform 1 [Homo sapiens] | VLLSWKVLDFSGPVPQGTGQPCSCGHW | HLA-A*02:01 | Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses. Front Oncol 2021 |
| solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 | KYAVAVGSLCALSSSLLGSMFPMPRVI | HLA-A*02:01 | Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses. Front Oncol 2021 |
| PLCG1 variant protein | SIEDHCSIAQQRNLAQYFKKVLGDTLL | HLA-A*02:01 | Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses. Front Oncol 2021 |
| Protein phosphatase Slingshot homolog 1 | ILDASKQRHNKLWCQQTDSSLQQPVDD | HLA-A*02:01 | Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses. Front Oncol 2021 |
| Acyl-Coenzyme A dehydrogenase family, member 8 | QTDVGGSGLSRLDISVIFEALATGCTS | HLA-A*02:01 | Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses. Front Oncol 2021 |
| breast cancer anti-estrogen resistance protein 1 isoform 1 [Homo sapiens] | VLLSWKVLDFSGPVPQGTGQPCSCGHW | HLA-A*02:01 | Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses. Front Oncol 2021 |
| PLCG1 variant protein | SIEDHCSIAQQRNLAQYFKKVLGDTLL | HLA-A*02:01 | Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses. Front Oncol 2021 |
| ran-binding protein 9 [Homo sapiens] | SSAAAPFPL | HLA-C*03:04 | Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat Biotechnol 2018 |
| 3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial isoform 1 precursor [Homo sapiens] | FVSTSDIKSM | HLA-C*03:04 | Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat Biotechnol 2018 |
| Dual specificity mitogen-activated protein kinase kinase 4 | KELLKHPFTL | HLA-A*02:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Dual specificity mitogen-activated protein kinase kinase 4 | FTLMYEERAV | HLA-A*02:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Serine-protein kinase ATM | YMKSLEFENK | HLA-A*11:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Epidermal growth factor receptor | KITDFGRAK | HLA-A*11:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Epidermal growth factor receptor | KITDFGRAK | HLA-A*11:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Epidermal growth factor receptor | VKITDFGRAK | HLA-A*11:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Epidermal growth factor receptor | ITDFGRAKL | HLA-C*01:02 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Epidermal growth factor receptor | HVKITDFGRAK | HLA-A*11:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Cellular tumor antigen p53 | STPLPGTRVR | HLA-A*11:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Epidermal growth factor receptor | RILKVTEFK | HLA-A*11:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Epidermal growth factor receptor | LRILKVTEFK | HLA-A*11:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Fibroblast growth factor receptor 2 | YMMMWDCWHA | HLA-A*02:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Fibroblast growth factor receptor 2 | YMMMWDCWHAV | HLA-A*02:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Epidermal growth factor receptor | KITDFGRAK | HLA-A*11:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Epidermal growth factor receptor | KITDFGRAK | HLA-A*11:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Epidermal growth factor receptor | AIKESPKANK | HLA-A*11:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Epidermal growth factor receptor | KITDFGRAK | HLA-A*11:01 | Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer 2021 |
| Metalloreductase STEAP1 | FLYTLLREV | HLA-A*02:01 | STEAP, a prostate tumor antigen, is a target of human CD8+ T cells. Cancer Immunol Immunother 2006 |
| Epidermal growth factor receptor | IPVAIKTSPK | HLA-A*11:01 | Identification of Clonal Neoantigens Derived From Driver Mutations in an -Mutated Lung Cancer Patient Benefitting From Anti-PD-1. Front Immunol 2020 |
| Epidermal growth factor receptor | AIKTSPKANK | HLA-A*11:01 | Identification of Clonal Neoantigens Derived From Driver Mutations in an -Mutated Lung Cancer Patient Benefitting From Anti-PD-1. Front Immunol 2020 |
| Cellular tumor antigen p53 | RVRAMTIYKQ | HLA-A*11:01 | Identification of Clonal Neoantigens Derived From Driver Mutations in an -Mutated Lung Cancer Patient Benefitting From Anti-PD-1. Front Immunol 2020 |
| Protein DENND6B | QLLKGVQKK | HLA-A*11:01 | Identification of Clonal Neoantigens Derived From Driver Mutations in an -Mutated Lung Cancer Patient Benefitting From Anti-PD-1. Front Immunol 2020 |
| CTF18, chromosome transmission fidelity factor 18 homolog (S. cerevisiae), isoform CRA_a | LLLDIVAPK | HLA-A*11:01 | Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016 |
| tegument protein pp65 [Human betaherpesvirus 5] | GPISGHVLK | HLA-A*11:01 | Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016 |
| Epstein-Barr nuclear antigen 4 | AVFDRKSDAK | HLA-A*11:01 | Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016 |
| CTF18, chromosome transmission fidelity factor 18 homolog (S. cerevisiae), isoform CRA_a | LLLDIVAPK | HLA-A*11:01 | Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016 |
| NADP-dependent malic enzyme | FLDEFMEGV | HLA-A*02:01 | High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001 |
| NADP-dependent malic enzyme | FLDEFMEAV | HLA-A*02:01 | High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001 |
| NADP-dependent malic enzyme | FLDEFMEGV | HLA-A*02:01 | High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001 |
| NADP-dependent malic enzyme | FLDEFMEGV | HLA-A*02:01 | High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001 |
| NADP-dependent malic enzyme | FLDEFMEAV | HLA-A*02:01 | High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001 |
| NADP-dependent malic enzyme | FLDEFMEGV | HLA-A*02:01 | High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001 |
| NADP-dependent malic enzyme | FLDEFMEAV | HLA-A*02:01 | High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001 |
| NADP-dependent malic enzyme | FLDEFMEGV | HLA-A*02:01 | High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001 |
| NADP-dependent malic enzyme | FLDEFMEAV | HLA-A*02:01 | High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001 |
| NADP-dependent malic enzyme | FLDEFMEAV | HLA-A*02:01 | High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001 |
| NADP-dependent malic enzyme | FLDEFMEAV | HLA-A*02:01 | High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival. Cancer Res 2001 |
| Alpha-actinin-1 | FIASNGVKLV | HLA-A*02:01 | A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001 |
| Alpha-actinin-1 | FIASNGVKLV | HLA-A*02:01 | A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001 |
| Alpha-actinin-1 | FIASNGVKLV | HLA-A*02:01 | A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001 |
| Alpha-actinin-1 | FIASNGVKLV | HLA-A*02:01 | A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001 |
| Alpha-actinin-1 | FIASNGVKLV | HLA-A*02:01 | A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res 2001 |
| EGFR protein | MQLMPFGCLL | HLA-A*02:01 | EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation. PLoS One 2013 |
肿瘤突变抗原清单使用方法：
肿瘤微环境研究：
检测肿瘤浸润淋巴细胞中，肿瘤抗原特异性淋巴细胞的数量实现。具体方式是：根据清单内容，将抗原肽和HLA合成为抗原肽MHC复合物荧光四聚体，通过流式细胞检测方法，检测肿瘤浸润淋巴细胞的含量。
肿瘤免疫细胞的全身分布：
通过检测外周血中肿瘤抗原特异性淋巴细胞的数量实现。具体方法同上。
过继性肿瘤免疫细胞治疗：
使用清单中抗原肽，刺激淋巴细胞，而后使用抗原肽MHC复合物荧光四聚体或磁珠四聚体，通过流式分选或磁珠分选细胞，经体外细胞增殖后，回输体内，评估肿瘤抑制效果。
肿瘤抗原特异性TCR测序：
通过肿瘤浸润淋巴细胞、或外周血淋巴细胞，通过分选后进行单细胞TCR测序，获得抗原特异性T细胞的TCR序列，进一步进行TCR-T疗法研究。
肿瘤疫苗片段筛选：
综合上述过程，获得具有激活T细胞杀伤肿瘤细胞的经验证抗原肽MHC复合物，用于肿瘤疫苗构建。